Trial Profile
Long-Term Extension of the Multinational, Double-Blind, Placebo Controlled Studies PDY6045 and PDY6046 to Document the Safety of Teriflunomide When Added to Treatment With Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis With Relapses.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary) ; Glatiramer acetate; Interferon beta
- Indications Multiple sclerosis
- Focus Adverse reactions
- 10 Jan 2012 Actual patient number is 182 according to ClinicalTrials.gov.
- 08 Jun 2011 Actual initiation date changed from Nov 2007 to Oct 2007 as reported by ClinicalTrials.gov.
- 15 Oct 2010 According to a Sanofi aventis media release, results of this trial were presented at the European Committee for Treatment andResearch in Multiple Sclerosis (ECTRIMS) congress.